On October 21, biotechnology company PerturbAI announced a collaboration with OpenAI and Scripps Research to develop an AI reasoning framework that uses thousands of agents to analyze biological data, search literature, and propose testable hypotheses, aiming to accelerate biomedical research and explore new drug targets.